Biogen and Alcyone Therapeutics partner up on novel device for neurological ASO therapies 05-Jan-2023 By Rachel Arthur Biogen and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx System.
Novartis’ gene therapy approved, heralding new era of pricing 27-May-2019 By Ben Hargreaves Novartis receives US FDA approval for its gene therapy, Zolgensma, which is a treatment for spinal muscular atrophy, and prices the drug at $2.1m per patient.